Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Perspectives on patient selection for CAR-T therapy

Ulrich Jäger • 10 Jun 2022
EHA 2022
General CAR-T

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses patient selection for CAR-T therapy, drawing focus on factors that need to be considered when selecting patients and the process of patient selection in the Austrian CAR-T cell network. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Ulrich Jäger

2:33
The effect of lymphodepleting agents on rate and severity of toxicities following CAR-T infusion
Ulrich Jäger • 16 Feb 2024
1:20
The importance of lymphodepletion, an undervalued component of the CAR-T therapy cycle
Ulrich Jäger • 16 Feb 2024
3:31
The role of lymphodepletion in CAR T-cell therapy: current knowledge & the need for personalization
Ulrich Jäger • 16 Feb 2024
0:58
CAR-T therapy in non-Hodgkin lymphoma: current status and future outlooks
Ulrich Jäger • 10 Feb 2023

Related Videos

2:09
The difficulty in developing predictive potency assays
Valentin Ortiz-Maldonado • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals